{"meta":{"query_hash":"a66805de879b","filters":{"venue":"Leukemia Research Reports"},"cohort_total":8,"direct_labels_cover":0,"predictions_cover":8,"exported":8,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a66805de879b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Leukemia+Research+Reports"},"results":[{"id":"W2057466968","doi":"10.1016/j.lrr.2014.06.003","title":"An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes","year":2014,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Takeda Oncology","keywords":"Medicine; Nausea; Neutropenia; Internal medicine; Adverse effect; Febrile neutropenia; Leukemia; Myeloid leukemia; Myelodysplastic syndromes; Oncology; Gastroenterology; Bone marrow; Toxicity","score_opus":0.05372415204847806,"score_gpt":0.37175913493930307,"score_spread":0.318034982890825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057466968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890198,0.0013577595,0.0010427104,0.00056707347,0.00010295442,0.0044853,0.0013112812,0.00008051238,0.0020326416],"genre_scores_gemma":[0.98079324,0.0018649183,0.0040022726,0.0009883178,0.00013841492,0.0052236035,0.003198966,0.00003381613,0.0037565187],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996618,0.00015810526,0.000011343708,0.000048207887,0.000031293635,0.00008927131],"domain_scores_gemma":[0.99943477,0.000095474184,0.00006720312,0.000044663175,0.000040984414,0.0003168382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015851461,0.0013002248,0.0013139202,0.00042906342,0.00036603745,0.00066826434,0.0007202417,0.0010444323,0.0029639108],"category_scores_gemma":[0.0007263875,0.00044020807,0.0011684641,0.00032470725,0.0006777905,0.0005246966,0.00036805033,0.0022727316,0.0005810645],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4419826,0.19666193,0.0128365075,0.001097437,0.0016460002,0.0016851722,0.00082918565,0.0072884047,0.16638926,0.0011602492,0.009497926,0.15892531],"study_design_scores_gemma":[0.36317804,0.6015944,0.014820312,0.000040597508,0.000500849,0.0007114408,0.00012707955,0.0023364024,0.009829072,0.00050943124,0.0063207587,0.000031702275],"about_ca_topic_score_codex":0.0012685801,"about_ca_topic_score_gemma":0.0034018236,"teacher_disagreement_score":0.0029639108,"about_ca_system_score_codex":0.0005934468,"about_ca_system_score_gemma":0.0017518395,"threshold_uncertainty_score":0.009915233},"labels":[],"label_agreement":null},{"id":"W2120357152","doi":"10.1016/j.lrr.2013.12.001","title":"Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"Eisai; Yuhan; National Comprehensive Cancer Network; Teva Pharmaceutical Industries","keywords":"Medicine; Creatinine; White blood cell; Internal medicine; Decitabine; Renal function; Cytarabine; Myeloid leukemia; Gastroenterology; Myeloid","score_opus":0.01774550426879862,"score_gpt":0.27612538088007427,"score_spread":0.25837987661127565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120357152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991278,0.0006188139,0.000030830244,0.000038992894,0.0000062294334,0.000019191593,0.00005056176,0.0000017115331,0.00010604251],"genre_scores_gemma":[0.9995084,0.00013056399,0.000075689415,0.000039156013,0.000015080504,0.000020736903,0.000118294265,5.3402806e-7,0.00009147945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968493,0.0001625858,0.000038232014,0.00003342392,0.00004378876,0.00003705305],"domain_scores_gemma":[0.99886227,0.00038223347,0.00040712257,0.00004519285,0.000070772534,0.00023244978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012410969,0.000167352,0.00051678385,0.00017929634,0.0001506115,0.00020025678,0.0001342005,0.0001958369,0.0008478254],"category_scores_gemma":[0.0017145012,0.00008536083,0.00025674512,0.00022295906,0.000110056084,0.00020033965,0.00015589151,0.00037490675,0.000096816926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06984251,0.0018733654,0.8803849,0.00016793571,0.00075396895,0.00009291297,0.000093755894,0.000556896,0.004512129,0.000023336552,0.00049497496,0.041203376],"study_design_scores_gemma":[0.0033173435,0.029125184,0.9648122,0.000024119794,0.00042836738,0.00021212985,0.00006212647,0.00056870386,0.0008630199,0.00003785699,0.00054246053,0.00000655805],"about_ca_topic_score_codex":0.000258893,"about_ca_topic_score_gemma":0.0006357963,"teacher_disagreement_score":0.0012410969,"about_ca_system_score_codex":0.00016410218,"about_ca_system_score_gemma":0.00016866048,"threshold_uncertainty_score":0.0065636635},"labels":[],"label_agreement":null},{"id":"W2168088054","doi":"10.1016/j.lrr.2015.07.003","title":"A radiolabeled antibody targeting CD123+ leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML","year":2015,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research; CSL Limited","keywords":"Radioimmunotherapy; Interleukin-3 receptor; Nod; Medicine; Cancer research; Leukemia; Bone marrow; Stem cell; Monoclonal antibody; Spleen; Immunology; Antibody; Biology; Endocrinology; Cell biology","score_opus":0.1673720073511262,"score_gpt":0.463160429935388,"score_spread":0.29578842258426175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168088054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457633,0.0009441829,0.0027394048,0.00007723859,0.000018969331,0.0000972563,0.00029291018,0.00011490223,0.0011388325],"genre_scores_gemma":[0.99115795,0.0011673437,0.004156557,0.00005375778,0.000020690219,0.00011137404,0.00069827394,0.000048262205,0.0025857228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998248,0.000034237462,0.000016708778,0.00004035244,0.000033354216,0.00005060104],"domain_scores_gemma":[0.9999021,0.000018821458,0.000023212117,0.000014199271,0.000010815885,0.000030761203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033612506,0.00045416938,0.0005937543,0.00036056273,0.0001859167,0.0002524073,0.00028663073,0.00039306658,0.00088927726],"category_scores_gemma":[0.0001022003,0.000191202,0.00029808574,0.00021643878,0.00033816058,0.0002595185,0.00015359095,0.0008266797,0.00037002255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021948136,0.00012480973,0.00009048713,0.000022918954,0.0000050338094,0.000027567132,0.000020673071,0.00008757225,0.9984199,0.00006299093,0.000024021032,0.000894563],"study_design_scores_gemma":[0.00003343174,0.0020263495,0.0010571543,0.000002220791,0.00002532408,0.00020178905,0.000009041401,0.00054212485,0.9953101,0.000021581633,0.0007677814,0.000003057265],"about_ca_topic_score_codex":0.0009349608,"about_ca_topic_score_gemma":0.0007655837,"teacher_disagreement_score":0.0009349608,"about_ca_system_score_codex":0.00028108485,"about_ca_system_score_gemma":0.00021871993,"threshold_uncertainty_score":0.0029749274},"labels":[],"label_agreement":null},{"id":"W4283744241","doi":"10.1016/j.lrr.2022.100335","title":"The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics","year":2022,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Monoclonal antibody; Antibody; Immunogenicity; Hybridoma technology; Computational biology; Molecular biology; Biology; Immunology","score_opus":0.034008251335591856,"score_gpt":0.3611706860590909,"score_spread":0.32716243472349904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283744241","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011680929,0.9576124,0.012182897,0.009018474,0.0012773692,0.00002553748,0.00006806489,0.00010239942,0.008031945],"genre_scores_gemma":[0.071838334,0.89615285,0.011968068,0.007972673,0.0016665021,0.000095060845,0.00013060599,0.0000474202,0.010128472],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970955,0.00007519048,0.00002550724,0.00005030998,0.00010877573,0.000030668878],"domain_scores_gemma":[0.9998355,0.000076838616,0.000023021928,0.000008966702,0.00003363124,0.000022039589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008575611,0.00031818452,0.00054752023,0.0005086331,0.00018771293,0.0010288865,0.0005186286,0.0010470075,0.0006979932],"category_scores_gemma":[0.00058617815,0.00019230944,0.00026132233,0.00050651137,0.0011282585,0.0016345319,0.00045795547,0.0019456706,0.0005434554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028713257,0.00012779667,0.00083111075,0.005907092,0.00012258012,0.0013314586,0.0008290489,0.0018645428,0.14521185,0.2231145,0.032118607,0.5882543],"study_design_scores_gemma":[0.00002358862,0.00028950442,0.0007500835,0.00042891383,0.000038431845,0.001876513,0.0001231778,0.00053353945,0.019319596,0.024544915,0.95204234,0.000029400526],"about_ca_topic_score_codex":0.00025445002,"about_ca_topic_score_gemma":0.0002419312,"teacher_disagreement_score":0.0010470075,"about_ca_system_score_codex":0.0005432835,"about_ca_system_score_gemma":0.00054503215,"threshold_uncertainty_score":0.004535258},"labels":[],"label_agreement":null},{"id":"W4321203706","doi":"10.1016/j.lrr.2023.100364","title":"Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Cart; Chimeric antigen receptor; Lymphoblastic Leukemia; Internal medicine; Leukemia; Oncology; Immunology; Cancer; Immunotherapy","score_opus":0.02381273821878506,"score_gpt":0.3316124645774158,"score_spread":0.30779972635863073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321203706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988715,0.0005210394,0.000028807355,0.000034193796,0.0000055841133,0.000006559807,0.00011508412,0.000001404263,0.00041584964],"genre_scores_gemma":[0.99942577,0.00026086732,0.000045238747,0.000038557017,0.000012870069,0.0000059435074,0.00012814741,4.6051437e-7,0.000082260936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999782,0.000053305015,0.000030247122,0.000028918983,0.000044329565,0.000061157414],"domain_scores_gemma":[0.9992009,0.00008441698,0.0005000065,0.000011777307,0.000040621344,0.00016226163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002610793,0.00020611272,0.00027057383,0.00043183315,0.00032702668,0.00045816545,0.00013401227,0.00027491845,0.0011448408],"category_scores_gemma":[0.0010256129,0.00014001687,0.00025603475,0.0005060671,0.00014634347,0.0003177226,0.00026211783,0.00044545616,0.00015425774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007934009,0.000035241184,0.9986494,0.000006172148,0.000013883706,0.00017736197,0.000018294117,0.000010262108,0.000057108333,0.0000061743385,0.000041019906,0.00090561155],"study_design_scores_gemma":[0.000009748965,0.0002170102,0.9975575,0.000010973941,0.000027126855,0.0017202909,0.00018111693,0.000075365955,0.0000386191,0.000018423027,0.00014149174,0.000002246159],"about_ca_topic_score_codex":0.0021127576,"about_ca_topic_score_gemma":0.0030961125,"teacher_disagreement_score":0.0021127576,"about_ca_system_score_codex":0.00022992899,"about_ca_system_score_gemma":0.00030982497,"threshold_uncertainty_score":0.0042008758},"labels":[],"label_agreement":null},{"id":"W4401434212","doi":"10.1016/j.lrr.2024.100477","title":"Successful treatment of AML using non-intensive chemotherapy in Jehovah's Witness patients","year":2024,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; Azacitidine; Arsenic trioxide; Induction chemotherapy; Myeloid leukemia; Chemotherapy; Intensive care medicine; Venetoclax; Internal medicine; Platelet transfusion; Leukemia; Blood transfusion; Retinoic acid; Oncology; Surgery; Platelet; Apoptosis","score_opus":0.05773487502074421,"score_gpt":0.3972080560227886,"score_spread":0.3394731810020444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401434212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913421,0.0009483673,0.00084751326,0.00045929351,0.000031468855,0.000050738843,0.000026808346,0.000018498844,0.006275308],"genre_scores_gemma":[0.998024,0.00062159146,0.0004789774,0.00020564286,0.000034873425,0.000014950475,0.000034869536,0.0000079086,0.00057721976],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99991226,0.000022787059,0.000011392394,0.000010824208,0.000011673907,0.00003098629],"domain_scores_gemma":[0.99982953,0.00003469321,0.000056062723,0.000014377776,0.0000057829297,0.000059484693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011710467,0.0001559785,0.00016144017,0.00022355487,0.0006813013,0.00032498845,0.00020342639,0.0005253449,0.0009869152],"category_scores_gemma":[0.0008450611,0.00008509864,0.00020455742,0.0001770241,0.00032783675,0.00024785716,0.00054573914,0.0005228556,0.00021742417],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057880126,0.00048676686,0.19661184,0.00017487463,0.000044811615,0.6862416,0.0034878745,0.000665991,0.028726947,0.0020058646,0.0019283092,0.07904633],"study_design_scores_gemma":[0.00012130741,0.0011643461,0.12613142,0.00012589242,0.00006167538,0.8253646,0.002429429,0.0008370379,0.021333182,0.001010167,0.021385236,0.000035656456],"about_ca_topic_score_codex":0.00038511193,"about_ca_topic_score_gemma":0.001100612,"teacher_disagreement_score":0.0009869152,"about_ca_system_score_codex":0.00019771424,"about_ca_system_score_gemma":0.00024518988,"threshold_uncertainty_score":0.0033015013},"labels":[],"label_agreement":null},{"id":"W4402469124","doi":"10.1016/j.lrr.2024.100480","title":"Diagnostic challenges in classification of plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia in the context of secondary-type mutations","year":2024,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Context (archaeology); Myeloid; Plasmacytoid dendritic cell; Cancer research; Immunology; Dendritic cell; Biology; Antigen","score_opus":0.06895311397010734,"score_gpt":0.356519635197072,"score_spread":0.2875665212269647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402469124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9282187,0.01098642,0.034512147,0.0054555084,0.0010246189,0.00033866643,0.0006073799,0.0004728448,0.01838363],"genre_scores_gemma":[0.98031026,0.0012153804,0.01680076,0.0005221332,0.00043969785,0.00004702386,0.0003144993,0.00003939154,0.00031071878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965624,0.0010070559,0.0005818839,0.0005192956,0.000632134,0.0006972466],"domain_scores_gemma":[0.9935174,0.0024846022,0.00063565484,0.000671967,0.0019591642,0.0007312185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006800382,0.0007197075,0.0008420315,0.0034960036,0.001260071,0.003304146,0.0027129927,0.0016482499,0.0020849758],"category_scores_gemma":[0.013716907,0.0004235475,0.00053845346,0.0009116873,0.0014579431,0.0018587144,0.0017976741,0.0018859862,0.0011446396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011501829,0.00024824493,0.6970836,0.000759799,0.00013275573,0.06258812,0.0017376115,0.001721385,0.058004268,0.006796238,0.008990056,0.1607878],"study_design_scores_gemma":[0.0001703955,0.0007256967,0.25222683,0.0014084912,0.0006247859,0.5491732,0.01282989,0.050221384,0.046868727,0.028163565,0.057437014,0.00015001213],"about_ca_topic_score_codex":0.0011403238,"about_ca_topic_score_gemma":0.0014001535,"teacher_disagreement_score":0.006800382,"about_ca_system_score_codex":0.00080652547,"about_ca_system_score_gemma":0.00089754805,"threshold_uncertainty_score":0.03596431},"labels":[],"label_agreement":null},{"id":"W4405557300","doi":"10.1016/j.lrr.2024.100495","title":"Targeting menin for precision therapy in high-risk acute myeloid leukemia","year":2024,"lang":"en","type":"review","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hamilton Health Sciences; University of Ottawa","funders":"","keywords":"Medicine; Myeloid leukemia; Cancer research; Oncology; Internal medicine","score_opus":0.08567478413901318,"score_gpt":0.43046841234776895,"score_spread":0.34479362820875575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405557300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008611889,0.99863005,0.000091582464,0.0003024642,0.0002039736,0.0000065935847,0.000022270822,0.0000073450133,0.0006497703],"genre_scores_gemma":[0.00063383224,0.9984577,0.00014014194,0.00025602375,0.00012665648,0.000008551469,0.000033888133,0.0000014588794,0.00034176075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977034,0.00005093739,0.000044629072,0.00003092324,0.000083295905,0.000019903888],"domain_scores_gemma":[0.9996624,0.00018602627,0.00005267126,0.000008483112,0.000072467476,0.00001794423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006338303,0.0005321466,0.0009705631,0.0017561762,0.00018671472,0.000934609,0.0006360078,0.0007479353,0.0049754],"category_scores_gemma":[0.0010517761,0.00017814607,0.000679451,0.0010292624,0.0002766201,0.0010290939,0.0005716711,0.0013387812,0.0017580154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008201843,0.000027469168,0.00011183851,0.030443994,0.0001924578,0.00011342163,0.000046539,0.0002634656,0.0014270939,0.0027158584,0.030152187,0.9344236],"study_design_scores_gemma":[0.000030955565,0.00008630274,0.00051635434,0.010130652,0.00032798265,0.00088355003,0.000044645574,0.00007571334,0.0005081088,0.0014960308,0.98588586,0.000013816923],"about_ca_topic_score_codex":0.0006163556,"about_ca_topic_score_gemma":0.0014393918,"teacher_disagreement_score":0.0049754,"about_ca_system_score_codex":0.0005177468,"about_ca_system_score_gemma":0.0011715669,"threshold_uncertainty_score":0.016644418},"labels":[],"label_agreement":null}]}